Monte Rosa Therapeutics presents preclinical data on MRT-6160

Monte Rosa Therapeutics announced the company will present preclinical data at the European Alliance of Associations for Rheumatology, EULAR, 2024 Congress, being held June 12-15 in Vienna, Austria. The data demonstrated that in a collagen-induced arthritis murine model, oral dosing of MRT-6160 inhibited disease progression as compared to vehicle and anti-TNF, concomitant with reduced serum pro-inflammatory cytokines and anti-collagen II autoantibodies. In vitro, MRT-6160-mediated degradation of human VAV1 dose-dependently reduced T-cell receptor- and B-cell receptor -mediated activation, proliferation, and function in T- and B-cells, including cytokine and IgG secretion.